|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marx V: Tracking metastasis and tricking
cancer. Nature. 494:133–136. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cairns RA, Khokha R and Hill RP: Molecular
mechanisms of tumor invasion and metastasis: An integrated view.
Curr Mol Med. 3:659–671. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cetin K, Ettinger DS, Hei YJ and O'Malley
CD: Survival by histologic subtype in stage IV nonsmall cell lung
cancer based on data from the surveillance, Epidemiology and end
results program. Clin Epidemiol. 3:139–148. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang Y, Ahn YH, Chen Y, Tan X, Guo L,
Gibbons DL, Ungewiss C, Peng DH, Liu X, Lin SH, et al: ZEB1
sensitizes lung adenocarcinoma to metastasis suppression by PI3K
antagonism. J Clin Invest. 124:2696–2708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Enomoto A, Murakami H, Asai N, Morone N,
Watanabe T, Kawai K, Murakumo Y, Usukura J, Kaibuchi K and
Takahashi M: Akt/PKB regulates actin organization and cell motility
via Girdin/APE. Dev Cell. 9:389–402. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohara K, Enomoto A, Kato T, Hashimoto T,
Isotani-Sakakibara M, Asai N, Ishida-Takagishi M, Weng L, Nakayama
M, Watanabe T, et al: Involvement of Girdin in the determination of
cell polarity during cell migration. PLoS One. 7:e366812012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ghosh P, Tie J, Muranyi A, Singh S,
Brunhoeber P, Leith K, Bowermaster R, Liao Z, Zhu Y, LaFleur B, et
al: Girdin (GIV) expression as a prognostic marker of recurrence in
mismatch repair-proficient stage II colon cancer. Clin Cancer Res.
22:3488–3498. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu C, Zhang Y, Xu H, Zhang R, Li H, Lu P
and Jin F: Girdin protein: A new potential distant metastasis
predictor of breast cancer. Med Oncol. 29:1554–1560. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peng WT, Hu X, Yao L, Jiang YZ and Shao
ZM: Elevated expression of Girdin in the nucleus indicates worse
prognosis for patients with estrogen receptor-positive breast
cancer. Ann Surg Oncol. 21 Suppl 4:S648–S656. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gu F, Wang L, He J, Liu X, Zhang H, Li W,
Fu L and Ma Y: Girdin, an actin-binding protein, is critical for
migration, adhesion, and invasion of human glioblastoma cells. J
Neurochem. 131:457–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shibata T, Matsuo Y, Shamoto T, Hirokawa
T, Tsuboi K, Takahashi H, Ishiguro H, Kimura M, Takeyama H and
Inagaki H: Girdin, a regulator of cell motility, is a potential
prognostic marker for esophageal squamous cell carcinoma. Oncol
Rep. 29:2127–2132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song JY, Jiang P, Li N, Wang FH and Luo J:
Clinical significance of Girdin expression detected by
immunohistochemistry in non-small cell lung cancer. Oncol Lett.
7:337–341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Buettner R, Mora LB and Jove R: Activated
STAT signaling in human tumors provides novel molecular targets for
therapeutic intervention. Clin Cancer Res. 8:945–954.
2002.PubMed/NCBI
|
|
15
|
Lui GY, Kovacevic Z, V Menezes S,
Kalinowski DS, Merlot AM, Sahni S and Richardson DR: Novel
thiosemicarbazones regulate the signal transducer and activator of
transcription3 (STAT3) pathway: Inhibition of constitutive and
interleukin 6-induced activation by iron depletion. Mol Pharmacol.
87:543–560. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dunkel Y, Ong A, Notani D, Mittal Y, Lam
M, Mi X and Ghosh P: STAT3 protein up-regulates Gα-interacting
vesicle-associated protein (GIV)/Girdin expression, and GIV
enhances STAT3 activation in a positive feedback loop during wound
healing and tumor invasion/metastasis. J Biol Chem.
287:41667–41683. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pan B, Shen J, Cao J, Zhou Y, Shang L, Jin
S, Cao S, Che D, Liu F and Yu Y: Interleukin-17 promotes
angiogenesis by stimulating VEGF production of cancer cells viathe
STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci Rep.
5:160532015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 6:649–655. 1982. View Article : Google Scholar
|
|
19
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L;
International Association for the Study of Lung Cancer
International Staging Committee, ; Participating Institutions, :
The IASLC lung cancer staging project: Proposals for the revision
of the TNM stage groupings in the forthcoming (seventh) edition of
the TNM Classification of malignant tumours. J Thorac Oncol.
2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Omori K, Asai M, Kuga D, Ushida K, Izuchi
T, Mii S, Enomoto A, Asai N, Nagino M and Takahashi M: Girdin is
phosphorylated on tyrosine 1798 when associated with structures
required for migration. Biochem Biophys Res Commun. 485:934–940.
2015. View Article : Google Scholar
|
|
21
|
Garcia-Marcos M, Ghosh P and Farquhar MG:
GIV/Girdin transmits signals from multiple receptors by triggering
trimeric G protein activation. J Biol Chem. 290:6697–6704. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Garcia-Marcos M, Jung BH, Ear J, Cabrera
B, Carethers JM and Ghosh P: Expression of GIV/Girdin, a
metastasis-related protein, predicts patient survival in colon
cancer. FASEB J. 25:590–599. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang A, Wang J, Sun L, Jin J, Ren H, Yang
F, Diao K, Wei M and Mi X: Expression of tumor necrosis factor
receptor-assicated factor 4 correlates with expression of Girdin
and promotes nuclear translocation of Girdin in breast cancer. Mol
Med Rep. 11:3635–3641. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nishimae K, Tsunoda N, Yokoyama Y, Kokuryo
T, Iwakoshi A, Takahashi M and Nagino M: The impact of Girdin
expression on recurrence-free survival in patients with
luminal-type breast cancer. Breast Cancer. 22:445–451. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yue P, Zhang X, Paladino D, Sengupta B,
Ahmad S, Holloway RW, Ingersoll SB and Turkson J: Hyperactive EGF
receptor, Jaks and Stat3 signaling promote enhanced colony-forming
ability, motility and migration of cisplatin-resistant ovarian
cancer cells. Oncogene. 31:2309–2322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun F, Zhang ZW, Tan EM, Lim ZLR, Li Y,
Wang XC, Chua SE, Li J, Cheung E and Yong EL: Icaritin suppresses
development of neuroendocrine differentiation of prostate cancer
through inhibition of IL-6/STAT3 and Aurora kinase a pathways in
TRAMP mice. Carcinogenesis. 37:701–711. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu JT, Li Y, Yu B, Gao GJ, Zhou T and Li
S: Girdin/GIV is upregulated by cyclic tension, propagates
mechanical signal transduction, and is required for the cellular
proliferation and migration of MG-63 cells. Biochem Biophys Res
Commun. 464:493–499. 2015. View Article : Google Scholar : PubMed/NCBI
|
